Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Goodwill (2016 - 2022)

Aytu Biopharma has reported Goodwill over the past 7 years, most recently at $8.6 million for Q1 2022.

  • Quarterly Goodwill fell 77.1% to $8.6 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Mar 2022, down 77.1% year-over-year, with the annual reading at $65.8 million for FY2021, 134.25% up from the prior year.
  • Goodwill was $8.6 million for Q1 2022 at Aytu Biopharma, down from $46.3 million in the prior quarter.
  • Over five years, Goodwill peaked at $65.8 million in Q2 2021 and troughed at $8.6 million in Q1 2022.
  • The 4-year median for Goodwill is $28.1 million (2020), against an average of $32.9 million.
  • Year-over-year, Goodwill surged 134.25% in 2021 and then crashed 77.1% in 2022.
  • A 4-year view of Goodwill shows it stood at $15.4 million in 2019, then skyrocketed by 82.56% to $28.1 million in 2020, then soared by 65.0% to $46.3 million in 2021, then tumbled by 81.37% to $8.6 million in 2022.
  • Per Business Quant, the three most recent readings for AYTU's Goodwill are $8.6 million (Q1 2022), $46.3 million (Q4 2021), and $46.3 million (Q3 2021).